BEBT-908 with chemo for adults with certain leukemia in remission
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called BEBT-908 combined with chemotherapy for adults with a specific type of acute lymphoblastic leukemia (ALL) who are in remission but still have small amounts of cancer cells (MRD positive). The goal is to see if this combination can get rid of those remaining cells and reduce the risk of relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have B-cell precursor acute lymphoblastic leukemia (BCP-ALL) with a MEF2D gene rearrangement, or you have a pre-B type that is Philadelphia chromosome negative.
- You are in complete remission (bone marrow has less than 5% blasts) but have minimal residual disease (MRD) that is positive (detected by sensitive tests).
- You are physically able to care for yourself (ECOG performance status 0-2).
- Your heart, liver, and kidney function are within acceptable limits.
- You are not pregnant or breastfeeding, and you are willing to use contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a CAR-T cell therapy (CNCT19) for people with B-cell acute lymphoblastic leukemia (B-ALL) who still have a tiny amount of cancer cells after standard treatment. The goal is to see if this therapy can clear those remaining cancer cells.
This trial tests a new cell therapy called obecabtagene autoleucel (a 'living drug' made from your own immune cells) for people with a type of blood cancer (B-cell ALL) that has responded to initial treatment but may still have tiny traces. The goal is to see if it can prevent relapse after remission.
This Phase 2 trial tests a combination of medicines to treat Philadelphia chromosome–positive (Ph-positive) or BCR-ABL–positive acute lymphoblastic leukemia (ALL), including cases that have come back or did not respond. It may help by targeting specific leukemia signals while also aiming to improve disease control.
This trial tests a treatment plan for adults with a type of blood cancer called ALL that is newly diagnosed and not Philadelphia chromosome-positive. The goal is to see how well the treatment works and if it is safe for patients who have not had prior therapy.
This study tests whether the drug BEBT-908 can help people with a specific genetic change (MEF2D rearrangement) in their leukemia that has either come back, not responded to treatment, or left behind a small amount of disease. It aims to see how safe and effective the drug is in treating this subtype.
This trial tests a combination of low-dose chemotherapy and immune-targeted drugs for adults newly diagnosed with a specific type of leukemia. The goal is to find a treatment that is effective with fewer side effects.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.